Cohen Jordana B, Eddinger Kevin C, Locke Jayme E, Forde Kimberly A, Reese Peter P, Sawinski Deirdre L
Renal, Electrolyte, and Hypertension Division.
Department of Surgery, and.
Clin J Am Soc Nephrol. 2017 Jun 7;12(6):974-982. doi: 10.2215/CJN.10280916. Epub 2017 May 25.
Use of diabetic donor kidneys has been a necessary response to the donor organ shortage. Recipients of diabetic donor kidneys have higher mortality risk compared with recipients of nondiabetic donor kidneys. However, the survival benefit of transplantation with diabetic donor kidneys over remaining on the waitlist has not been previously evaluated.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed an observational cohort study of 437,619 kidney transplant candidates from the Organ Procurement and Transplantation Network database, including 8101 recipients of diabetic donor kidneys and 126,560 recipients of nondiabetic donor kidneys. We used time-varying Cox proportional hazards modeling to assess the mortality risk of accepting a diabetic donor kidney compared with remaining on the waitlist or receiving a nondiabetic donor kidney.
Among transplant recipients, median follow-up was 8.9 years and mortality rate was 35 deaths per 1000 person-years. Recipients of diabetic donor kidneys had 9% lower mortality compared with remaining on the waitlist or transplantation with a nondiabetic donor kidney (adjusted hazard ratio, 0.91; 95% confidence interval, 0.84 to 0.98). Although recipients of nondiabetic donor kidneys with a Kidney Donor Profile Index score >85% had lower mortality risk (adjusted hazard ratio, 0.86; 95% confidence interval, 0.81 to 0.91), recipients of diabetic donor kidneys with an index score >85% did not show any difference (adjusted hazard ratio, 1.09; 95% confidence interval, 0.97 to 1.22). Patients aged <40 years attained no survival benefit from transplantation with diabetic donor kidneys; diabetic patients at centers with long waitlist times attained the greatest survival benefit.
Diabetic donor kidneys appear associated with higher mortality risk compared with nondiabetic donor kidneys, but offer greater survival benefit compared with remaining on the waitlist for many candidates. Patients with high risk of mortality on the waitlist at centers with long wait times appear to benefit most from transplantation with diabetic donor kidneys.
使用糖尿病患者捐献的肾脏是应对供体器官短缺的必要举措。与接受非糖尿病患者捐献肾脏的受者相比,接受糖尿病患者捐献肾脏的受者死亡风险更高。然而,此前尚未评估接受糖尿病患者捐献肾脏进行移植相对于继续等待名单上等待所带来的生存益处。
设计、地点、参与者与测量方法:我们对器官获取与移植网络数据库中的437,619名肾脏移植候选者进行了一项观察性队列研究,其中包括8101名接受糖尿病患者捐献肾脏的受者和126,560名接受非糖尿病患者捐献肾脏的受者。我们使用时变Cox比例风险模型来评估接受糖尿病患者捐献肾脏相对于继续等待名单上等待或接受非糖尿病患者捐献肾脏的死亡风险。
在移植受者中,中位随访时间为8.9年,死亡率为每1000人年35例死亡。与继续等待名单上等待或接受非糖尿病患者捐献肾脏进行移植相比,接受糖尿病患者捐献肾脏的受者死亡率低9%(调整后风险比,0.91;95%置信区间,0.84至0.98)。虽然肾脏供体特征指数评分>85%的非糖尿病患者捐献肾脏的受者死亡风险较低(调整后风险比,0.86;95%置信区间,0.81至0.91),但指数评分>85%的糖尿病患者捐献肾脏的受者未显示出任何差异(调整后风险比,1.09;95%置信区间,0.97至1.22)。年龄<40岁的患者接受糖尿病患者捐献肾脏进行移植未获得生存益处;等待名单时间长的中心的糖尿病患者获得的生存益处最大。
与非糖尿病患者捐献的肾脏相比,糖尿病患者捐献的肾脏似乎与更高的死亡风险相关,但与许多候选者继续留在等待名单上相比,能提供更大的生存益处。在等待名单上死亡风险高且等待时间长的中心的患者似乎从接受糖尿病患者捐献肾脏进行移植中获益最大。